The Complement System is a network of more than 30 circulating and membrane-associated proteins that forms an important part of innate immunity while also interacting closely with adaptive immune responses. Complement proteins circulate largely as inactive precursors and become activated through tightly regulated enzymatic cascades. The principal activation routes are the classical pathway, lectin pathway, and alternative pathway.
Although these pathways begin differently, they converge on activation of complement component C3 and subsequently generate products that promote pathogen recognition, inflammation, immune-cell recruitment, and destruction of susceptible targets. Complement is particularly important for defence against extracellular microorganisms and for efficient clearance of immune complexes and damaged cellular material. It is not simply a collection of antibodies: antibodies can initiate the classical pathway, but several complement pathways can operate without antibodies.
The classical pathway is commonly initiated when complement component C1q recognises antibodies, particularly IgM or certain IgG subclasses, bound to an antigen. The lectin pathway begins when pattern-recognition molecules such as mannose-binding lectin or ficolins recognise characteristic carbohydrate structures on microbial surfaces. The alternative pathway can undergo continuous low-level spontaneous activation and becomes amplified when deposited complement fragments are stabilised on surfaces that lack effective regulatory mechanisms.
All three pathways ultimately generate C3 convertase, an enzyme complex that cleaves C3 into C3a and C3b. C3b can participate in formation of C5 convertase, linking early complement activation to the terminal pathway. This convergence provides redundancy while allowing complement to recognise pathogens through both antibody-dependent and antibody-independent mechanisms.
Complement produces several functionally important fragments. C3b and related fragments act as opsonins, coating microbial surfaces and making them easier for phagocytes to recognise and ingest through complement receptors. Small fragments such as C3a and C5a are anaphylatoxins that contribute to inflammatory signalling, vascular changes, and recruitment or activation of leukocytes. C5a is particularly important as a potent chemoattractant and inflammatory mediator.
The terminal complement pathway involves sequential assembly of components C5b through C9 into the membrane attack complex, commonly abbreviated MAC. The MAC can form pores in susceptible cell membranes, with Gram-negative bacteria being particularly vulnerable to this mechanism. Complement therefore combines recognition, amplification, inflammation, opsonisation, and direct membrane damage within one integrated system.
Complement activity must be tightly regulated because uncontrolled activation can damage host tissues. Regulatory proteins include factor H, factor I, CD46, CD55, CD59, and other molecules that limit activation, accelerate convertase decay, or prevent membrane attack complex formation on host cells. Host cells possess complement-regulatory mechanisms that distinguish them from many microbial surfaces. Genetic or acquired defects in these regulatory processes can produce excessive complement activation and tissue injury. Conversely, inadequate complement activity can impair microbial clearance. Complement is also involved in clearance of immune complexes and apoptotic material, meaning that abnormalities can contribute to inflammatory and autoimmune disease. The balance between activation and regulation is therefore central to complement physiology rather than being an incidental protective mechanism.
Complement deficiencies have characteristic clinical consequences depending on which component is affected. Deficiencies involving early classical-pathway components can increase susceptibility to certain bacterial infections and are also associated with autoimmune phenomena because immune-complex clearance may be impaired. C3 deficiency is particularly serious because C3 occupies a central position shared by the major activation pathways and deficiency can cause recurrent severe bacterial infections.
Deficiencies of terminal components can predispose especially to recurrent infections with Neisseria species because the membrane attack complex is important for defence against these organisms. Defects in complement regulators can produce different disorders involving excessive activation, such as hereditary angioedema in the case of C1 inhibitor deficiency or dysfunction. Complement testing therefore has diagnostic value in selected recurrent infections, autoimmune disorders, and complement-mediated diseases.
Complement is closely connected with adaptive immunity. Antibodies can activate the classical pathway, while complement fragments can influence B-cell responses and enhance antibody-mediated immune recognition. Complement receptors on immune cells allow complement-coated particles to interact with phagocytes and lymphocytes. Complement also participates in removal of immune complexes, helping prevent persistent deposition of antibody-antigen aggregates in tissues. Excessive or inappropriate complement activation can contribute to conditions such as systemic lupus erythematosus, certain kidney diseases, haemolytic processes, and inflammatory disorders.
Low circulating complement levels can sometimes indicate consumption during active immune-complex disease, although interpretation depends on the individual component tested and the clinical context. Complement measurements therefore need to be understood as part of a broader diagnostic assessment rather than treated as universal markers of inflammation.
Therapeutically, the Complement System has become an important target because excessive activation contributes to several diseases. Drugs can inhibit particular complement components or pathways, thereby reducing downstream inflammation or tissue injury. Therapeutic inhibition must be carefully balanced against increased susceptibility to infections because complement is an important host-defence mechanism. Vaccination and infection-prevention strategies can therefore be particularly relevant when terminal complement activity is pharmacologically blocked. Laboratory investigation can measure total complement activity, individual components, activation products, or pathway-specific function. Commonly measured components include C3 and C4, while functional assays can assess classical or alternative pathway activity. The usefulness of each test depends on the suspected disorder, and normal levels of individual proteins do not necessarily exclude all abnormalities of complement regulation or activation.
The Complement System is distinct from the coagulation system, although the two interact extensively during inflammation and tissue injury. Its name derives from the historical observation that a heat-sensitive component of blood "complemented" antibody-mediated antimicrobial activity. Modern understanding has shown that complement is a sophisticated surveillance and effector system rather than merely an accessory to antibodies. A common misconception is that complement always benefits the host; excessive or misdirected activation can cause substantial tissue damage.
Another misconception is that complement is exclusively part of innate immunity, because its activation by antibodies and effects on adaptive immune responses demonstrate substantial integration between innate and adaptive defence. Its biological importance lies in the regulated balance between rapid antimicrobial protection, immune-complex clearance, inflammatory signalling, and protection of the body's own cells.
